Dr Roberts is a highly experienced director and senior executive with 40 years' experience in the medical innovation space, and was the chief executive officer / president of Cochlear Limited (ASX:COH) from February 2004 to August 2015.
He was primarily responsible for the significant increase in Cochlear Limited's sales from $348 million in 2005 to $926 million in 2015.
Dr Roberts was also chairman of Sirtex Medical (ASX:SRX), from March 2000 to December 2002, and was executive vice-president of global sleep disorder treatment company ResMed Inc (NYSE:RMD, ASX:RMD) from 1992 to 2004.
Daniel Kenny, CEO, commented: "We are delighted to welcome someone of the calibre of Dr Roberts to our board of directors.
"Dr Roberts' outstanding track record of achievement across multiple disciplines in the commercialisation of medical innovation will be a valuable addition to the board, as the company continues to advance the commercialisation of OncoSil™ as a medical radiation treatment for pancreatic cancer and other solid tumours."
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.